Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | GAA | P10253 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.67 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.67 |
| ▸ | THRB | P10828 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | CASP1 | P29466 | 1/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
| ▸ | PLEC | Q15149 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | AURKA | O14965 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6414545 | 1.00 | MAPT (0.67) | MAPTKMT2AGAAMEN1L3MBTL1 | |
| SCHEMBL10055033 | 0.89 | LMNA (0.61) | MAPTKMT2AGAAMEN1L3MBTL1 | |
| SCHEMBL2005375 | 0.89 | MAPT (0.80) | MAPTKMT2AGAAMEN1L3MBTL1 | |
| SCHEMBL10055032 | 0.89 | MAPT (0.80) | MAPTKMT2AGAAMEN1L3MBTL1 | |
| SCHEMBL6419238 | 0.89 | LMNA (0.61) | MAPTKMT2AGAAMEN1L3MBTL1 | |
| SCHEMBL22783760 | 0.83 | MAPT (0.71) | MAPTKMT2AGAAMEN1L3MBTL1 | |
| SCHEMBL22674849 | 0.82 | MAPT (0.69) | MAPTKMT2AGAAMEN1L3MBTL1 | |
| SCHEMBL4592466 | 0.82 | MAPT (0.69) | MAPTKMT2AGAAMEN1L3MBTL1 | |
| SCHEMBL14950714 | 0.80 | MAPT (1.00) | MAPTKMT2AGAAMEN1L3MBTL1 | |
| SCHEMBL6416118 | 0.80 | MEN1 (0.67) | MAPTKMT2AGAAMEN1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115745808-B | Method for preparing secondary amine compound by catalyzing reduction of imine compound | 延安大学 | 2024-04-30 | — | — | CN | disclosed |
| CN-114875434-B | Electrochemical method for amination of imine compounds | 齐鲁工业大学 | 2023-08-11 | — | — | CN | disclosed |
| CN-115745808-A | Method for preparing secondary amine compound by catalyzing reduction of imine compound | 延安大学 | 2023-03-07 | — | — | CN | disclosed |
| EP-4081199-A2 | LIPOXYGENASE INHIBITORS | SRI International (US) | 2022-11-02 | — | — | EP | disclosed |
| CN-114875434-A | Electrochemical method for amination of imine compound | 齐鲁工业大学 | 2022-08-09 | — | — | CN | disclosed |
| CN-105693896-B | Acenaphthequinone-1, 2-asymmetric diimine nickel complex catalyst and preparation method and application thereof | 中国石油天然气股份有限公司 | 2018-02-02 | — | — | CN | disclosed |
| US-9266834-B2 | 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors | Janssen Pharmaceuticals, Inc. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9266834-B2 | 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors | Janssen Pharmaceuticals, Inc. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20140315903-A1 | 1, 4-Disubstituted 3-Cyano-Pyridone Derivatives and Their Use As Positive Allosteric Modulators of MGLUR2-Receptors | JANSSEN PHARMACEUTICALS INC (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140315903-A1 | 1, 4-Disubstituted 3-Cyano-Pyridone Derivatives and Their Use As Positive Allosteric Modulators of MGLUR2-Receptors | JANSSEN PHARMACEUTICALS INC (US) | 2014-10-23 | — | — | US | disclosed |
| US-8841323-B2 | 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors | Janssen Pharmaceuticals, Inc. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841323-B2 | 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors | Janssen Pharmaceuticals, Inc. (US) | 2014-09-23 | — | — | US | disclosed |
| EP-2426125-A1 | 1,4 disubstituted 3 cyano pyridone derivatives and their use as positive allosteric modulators of mGluR2 receptors | Ortho-McNeil-Janssen Pharmaceuticals, Inc. (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20100166655-A1 | 1, 4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-07-01 | — | — | US | disclosed |
| WO-2007104783-A2 | 1,4 -DI SUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2-RECEPT0R MODULATORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315903-A1 | 1, 4-Disubstituted 3-Cyano-Pyridone Derivatives and Their Use As Positive Allosteric Modulators of MGLUR2-Receptors | GRM2, GRM1, GRM3 | MAPT 2624/4885KMT2A 1837/4885GAA 4527/4885 |
| US-20100166655-A1 | 1, 4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | GRM2, GRM1, GRM3 | MAPT 2635/4885KMT2A 1844/4885GAA 4511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.